PharmaTomato raises seed round from enbo life to bring virtual trials into drug R&D

What's the deal? PharmaTomatoDealroom has a profile for this one. Try Dealroom → has closed its first funding round, a seed raise led by enbo life, the company announced in October 2026. The startup builds virtual clinical trials and medical AI agents for drug development.

What's the endgame? PharmaTomato aims to embed virtual trials and AI agents into the actual production workflow of pharmaceutical R&D. It fuses real-world data, historical trial data, protocol elements, and operational metrics into combined models.

How it works: The approach helps sponsors and contract research organisations (CROs) spot protocol risks, enrolment bottlenecks, and cost deviations before a trial starts. During execution, it enables finer-grained dynamic optimisation.

The signal: Clinical trials remain among the slowest, costliest stages of drug development. PharmaTomato's bet is that data-driven modelling can move trial design and management upstream — catching problems before they derail timelines and budgets.

Read more: itjuzi.com

Image credit: Generated with Gemini